$840.84
+30.60 (+3.78%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where REGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
354 interventional · 27 observational · 17 expanded access · 121 with posted results
Held by 23 tracked-famous managers (Dodge & Cox, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, Man Group plc, Qube Research & Technologies Ltd, +18 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · government filings 180d: 1 congress / 4 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T CellsNCT06798298observationalIncidence of delayed adverse events considered at least possibly related to prior gene modified T cell therapy | — | Recruiting | Genetic: Non-interventional | Long Term Safety Following GM T Cell Therapy | 50 | 2040-06-17 | in 5,050 d | 2026-07-08 |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received TreatmentNCT05828511Incidence of Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Linvoseltamab | Multiple Myeloma | 149 | 2035-11-02 | in 3,361 d | 2026-05-13 |
| A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia BNCT06379789Occurrence of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGV131, LNP1265 | Hemophilia B | 130 | 2034-08-14 | in 2,916 d | 2026-08-05 |
| A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple MyelomaNCT06669247Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamabNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Linvoseltamab, REGN7945+Linvoseltamab | Relapsed/Refractory Multiple Myeloma | 186 | 2033-11-11 | in 2,640 d | 2026-08-05 |
| A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple MyelomaNCT07455851Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamabNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Linvoseltamab, REGN17372+Linvoseltamab | Relapsed Refractory Multiple Myeloma (RRMM) | 150 | 2033-09-30 | in 2,598 d | 2026-08-05 |
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)NCT07393282Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteriaRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Linvoseltamab, Daratumumab | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | 2033-07-27 | in 2,533 d | 2026-08-18 |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaNCT05730036Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participantsRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone | Relapsed Refractory Multiple Myeloma (RRMM) | 410 | 2033-04-19 | in 2,434 d | 2026-03-06 |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaNCT03761108Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation periodNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Linvoseltamab | Multiple Myeloma | 387 | 2033-03-30 | in 2,414 d | 2026-04-20 |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple MyelomaNCT05955508Frequency of Adverse Events of Special Interest (AESI) during the safety run-in observation periodRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Linvoseltamab | Smoldering Multiple Myeloma (SMM) | 40 | 2033-01-25 | in 2,350 d | 2026-04-13 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaNCT07567469Occurrence of Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) | High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | 120 | 2032-08-27 | in 2,199 d | 2026-05-05 |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaNCT06140524Frequency of Adverse Events Interest (AEI) during the safety observation periodNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Linvoseltamab | Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | 116 | 2032-05-18 | in 2,098 d | 2026-07-08 |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerNCT04077099Number of patients with Dose Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGN5093 | NSCLC | 231 | 2032-04-22 | in 2,072 d | 2026-06-17 |
| First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)NCT06351592Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SODRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: ALN-SOD, Placebo (PB) · Other: Diluent | Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | 54 | 2032-03-21 | in 2,040 d | 2026-07-22 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersNCT07493304Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: REGN7508, Apixaban | Venous Thromboembolism (VTE) | 1,600 | 2031-07-08 | in 1,783 d | 2026-08-19 |
| Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 MutationNCT07753148Occurrence of Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: REGN17235 | Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) | 52 | 2031-05-05 | in 1,719 d | 2026-08-07 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaNCT06149286Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomideRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Odronextamab, Lenalidomide, Rituximab | Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | 580 | 2031-04-30 | in 1,714 d | 2026-08-14 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaNCT07594106Occurrence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | 2030-10-27 | in 1,529 d | 2026-08-05 |
| A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07154290Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Ubamatamab, Marlotamig, Sarilumab | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung | 300 | 2030-06-10 | in 1,390 d | 2026-08-13 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersNCT06469281Incidence of treatment emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Other: 27T51 · Drug: Cemiplimab, Bevacizumab | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 90 | 2030-05-27 | in 1,376 d | 2026-02-03 |
| A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of CareNCT06693531observationalDemographic characteristic of participants who receive dupilumab for EoE: Age | — | Active, not recruiting | Drug: dupilumab | Eosinophilic Esophagitis (EoE) | 368 | 2030-05-22 | in 1,371 d | 2026-08-12 |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell CarcinomaNCT06585410Event-Free Survival (EFS) as assessed by the investigatorRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Cemiplimab · Procedure: Standard of care | Cutaneous Squamous Cell Carcinoma (CSCC) | 369 | 2030-05-03 | in 1,352 d | 2026-08-17 |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerNCT05125016Incidence of Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGN4336, REGN5678 | Metastatic Castration-resistant Prostate Cancer | 228 | 2030-03-28 | in 1,316 d | 2026-05-05 |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910Percent change in liver fatRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALN-PNP, Tirzepatide, Placebo | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 204 | 2030-03-15 | in 1,303 d | 2026-08-10 |
| A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) DiseaseNCT07142343Incidence of Treatment-Emergent Adverse Event (TEAEs)Open-label · Treatment | Phase 4 | Recruiting | Drug: Pozelimab | CHAPLE Disease | 5 | 2030-02-12 | in 1,272 d | 2026-04-13 |
| A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has SpreadNCT07543055Occurrence of Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Recruiting | Genetic: BPX-601 | Prostate Cancer | 36 | 2030-02-05 | in 1,265 d | 2026-08-10 |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyNCT06413680Incidence of Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGN10597, Cemiplimab | Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors | 240 | 2030-02-03 | in 1,263 d | 2026-04-28 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisNCT07410117Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related deathRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: REGN7508, Placebo | Cancer-Associated Thrombosis (CAT) | 1,120 | 2030-01-23 | in 1,252 d | 2026-07-22 |
| A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyNCT07154745Percent change in Lactate Dehydrogenase (LDH) during TPOpen-label · Treatment | Phase 3 | Recruiting | Drug: Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | 35 | 2030-01-18 | in 1,247 d | 2026-08-05 |
| A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerNCT05800015Objective response rate (ORR) as assessed by blinded independent review committee (BICR) using RECIST 1.1Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo | Non-small Cell Lung Cancer | 160 | 2030-01-16 | in 1,245 d | 2026-07-15 |
| A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorNCT07187401Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ALN-CFB, Placebo | Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia | 24 | 2029-11-29 | in 1,197 d | 2026-07-09 |
| A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentNCT06848088Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613Non-randomized · Open-label · Other | Phase 2 | Enrolling by invitation | Drug: Fianlimab+cemiplimab | Melanoma | 48 | 2029-10-10 | in 1,147 d | 2026-07-13 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationNCT07626411Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolismRandomized · Quadruple-masked · Prevention | Phase 3 | Not yet recruiting | Drug: REGN7508, Apixaban, Placebo | Atrial Fibrillation (AF) | 15,364 | 2029-09-11 | in 1,118 d | 2026-06-04 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisNCT06975787Occurrence of Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Vonsetamig, Odronextamab | Lupus Nephritis (LN) | 90 | 2029-09-10 | in 1,117 d | 2026-08-13 |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseaseNCT07318610Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) deathRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: REGN7508, REGN9933, Placebo, Rivaroxaban | Peripheral Artery Disease (PAD) | 7,050 | 2029-08-18 | in 1,094 d | 2026-08-19 |
| A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaNCT06097364Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapyRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone | Follicular Lymphoma (FL) | 733 | 2029-07-29 | in 1,074 d | 2026-02-06 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07675824Occurrence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Not yet recruiting | Drug: REGN22530 | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | 271 | 2029-07-25 | in 1,070 d | 2026-06-30 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)NCT07697599Time-to-first event of centrally adjudicated VTE [symptomatic VTE or incidental VTE or asymptomatic VTE]Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: REGN7508, REGN9933, Placebo | Venous Thromboembolism (VTE) | 1,908 | 2029-06-25 | in 1,040 d | 2026-07-13 |
| First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)NCT07216066Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: ALN-SNCA, Placebo | Parkinsons Disease | 46 | 2029-06-07 | in 1,022 d | 2026-04-14 |
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat AllergyNCT07675811Ocular itch score in participants receiving REGN-2Cat as compared to placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo | Allergic Conjunctivitis | 570 | 2029-05-31 | in 1,015 d | 2026-08-12 |
| A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)NCT07222761Occurrence of Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 915 | 2029-05-21 | in 1,005 d | 2026-07-01 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableNCT07430956Time to first occurrence of ischemic stroke or systemic embolismRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Drug: REGN7508, REGN9933, Placebo | Atrial Fibrillation (AF) | 2,628 | 2029-03-28 | in 951 d | 2026-06-23 |
| A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin MutationsNCT05788536Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Genetic: DB-OTO | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | 36 | 2029-02-26 | in 921 d | 2026-08-05 |
| A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin LymphomasNCT05685173Incidence of Dose Limiting Toxicities (DLTs) of REGN5837 in combination with odronextamabNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Odronextamab, REGN5837 | B-cell Non-Hodgkins Lymphoma (B-NHL) | 107 | 2029-02-16 | in 911 d | 2026-05-19 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07631637Percent change from baseline in liver fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF)Randomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: ALN-CIDEB, Placebo | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | 150 | 2029-02-06 | in 901 d | 2026-06-08 |
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)NCT07559513Occurrence of Treatment-Emergent Adverse Event (TEAEs)Non-randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | 18 | 2028-12-10 | in 843 d | 2026-04-30 |
| An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNCT05363319observationalOverall survival (OS) | — | Recruiting | Drug: Cemiplimab, Platinum-based chemotherapy | Non-small Cell Lung Cancer | 500 | 2028-10-30 | in 802 d | 2026-07-24 |
| A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksNCT05744921Incidence of treatment-emergent serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | 202 | 2028-10-10 | in 782 d | 2026-07-30 |
| A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)NCT06292780Incidence of dose-limiting toxicity (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Linvoseltamab | Relapsed/Refractory Systemic Light Chain Amyloidosis | 220 | 2028-08-20 | in 731 d | 2026-08-18 |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyNCT06541704Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Pozelimab, Cemdisiran, Placebo | Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | 975 | 2028-07-31 | in 711 d | 2026-08-17 |
| This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationNCT07587658Time to first all-cause eventRandomized · Quadruple-masked · Treatment | Phase 4 | Not yet recruiting | Drug: dupilumab, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 754 | 2028-07-30 | in 710 d | 2026-05-14 |
| Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult ParticipantsNCT07230834Occurrence of ocular Treatment-Emergent Adverse Event (TEAEs) in the study eyeRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Pozelimab | Geographic Atrophy (GA) | 54 | 2028-07-03 | in 683 d | 2026-08-05 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerNCT06787612Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessmentRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 297 | 2028-06-30 | in 680 d | 2026-08-12 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisNCT07527923Occurrence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: REGN20423 · Other: Placebo | Healthy Volunteer, Atopic Dermatitis | 144 | 2028-06-23 | in 673 d | 2026-06-25 |
| A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisNCT07112378Incidence of treatment-emergent Serious Adverse Events (SAEs)Randomized · Single-masked · Treatment | Phase 3 | Recruiting | Drug: dupilumab | Eosinophilic Esophagitis (EoE) | 20 | 2028-06-19 | in 669 d | 2026-08-05 |
| A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06769698Overall Response Rate (ORR)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: FDC fianlimab+cemiplimab, Cemiplimab, Placebo | Head and Neck Squamous Cell Carcinoma (HNSCC) | 120 | 2028-06-04 | in 654 d | 2026-08-06 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaNCT06230224Event-free survival (EFS) as assessed by independent central review (ICR)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine | B-Cell Non-Hodgkin Lymphoma (B-NHL) | 216 | 2028-05-29 | in 648 d | 2026-05-11 |
| Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyNCT07220785Change in Hemoglobin A1c (HbA1c)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Mibavademab, Placebo | Generalized Lipodystrophy | 28 | 2028-05-19 | in 638 d | 2026-08-18 |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionNCT05519475Change in quantitative liver Fibrosis (qFibrosis)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALN-HSD, Placebo | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | 120 | 2028-04-27 | in 616 d | 2026-07-08 |
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaNCT06091865Incidence of Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | 2028-03-30 | in 588 d | 2026-08-06 |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsNCT05137054Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation periodNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab | Multiple Myeloma | 317 | 2028-03-25 | in 583 d | 2026-07-08 |
| Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)NCT07318597Change from baseline in Pulmonary Vascular Resistance (PVR)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: REGN13335, Placebo | Pulmonary Arterial Hypertension (PAH) | 99 | 2028-02-27 | in 556 d | 2026-08-19 |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaNCT06091254Incidence of Dose-Limiting Toxicities (DLTs) for odronextamabRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine | Follicular Lymphoma (FL) | 822 | 2028-02-07 | in 536 d | 2026-08-10 |
| A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)NCT05557591Objective response rate (ORR) as assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: BNT116, Cemiplimab | Advanced Non-Small Cell Lung Cancer | 51 | 2028-01-26 | in 524 d | 2026-05-06 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: Olatorepatide, Placebo | Overweight or Obesity | 360 | 2028-01-21 | in 519 d | 2026-07-06 |
| A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch AllergyNCT07710846observationalProportion of participants with moderate-to-severe allergic conjunctivitis due to cat allergy who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander | — | Not yet recruiting | Other: Noninterventional | Conjunctivitis Allergic | 1,500 | 2028-01-10 | in 508 d | 2026-07-17 |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaNCT03969004DFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cemiplimab, Placebo | Cutaneous Squamous Cell Carcinoma | 415 | 2028-01-07 | in 505 d | 2026-03-27 |
| A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)NCT05092347Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation periodOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Vonsetamig | Chronic Kidney Disease (CKD) | 43 | 2027-11-22 | in 459 d | 2026-06-02 |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGN5678, Cemiplimab | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 345 | 2027-11-15 | in 452 d | 2026-07-09 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)NCT07609940Occurrence of any grade CRS per American Society for Transplantation and Cellular Therapy (ASTCT) gradingOpen-label · Treatment | Phase 4 | Recruiting | Drug: Linvoseltamab, Tocilizumab | Relapsed/Refractory Multiple Myeloma (RRMM) | 30 | 2027-10-11 | in 417 d | 2026-07-29 |
| Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesNCT03233139Incidence and severity of treatment-emergent adverse events (TEAEs) in patients treated with cemiplimab as monotherapyNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy, Gemcitabine, Pemetrexed, Paclitaxel, Fianlimab | Advanced Malignancies | 146 | 2027-09-30 | in 406 d | 2026-02-12 |
| A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767Objective response rate (ORR) as assessed by blinded independent central review (BICR), using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: fianlimab, cemiplimab, Placebo | Advanced Non-Small Cell Lung Cancer | 149 | 2027-09-28 | in 404 d | 2026-07-02 |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney DiseaseNCT07271186Percent change in Urine Albumin to Creatinine Ratio (UACR)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: ALN-ANG3, Evinacumab, ALN-ANG3 placebo, Evinacumab placebo | Diabetic Kidney Disease (DKD) | 270 | 2027-09-24 | in 400 d | 2026-08-10 |
| Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyNCT06369467Incidence of Treatment-Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: linvoseltamab, dupilumab | Food Allergy | 6 | 2027-08-31 | in 376 d | 2026-06-26 |
| A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaNCT07235917Change from the highest serum estradiol observed during a 28-day periodRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Mibavademab · Other: Placebo | Functional Hypothalamic Amenorrhea (FHA) | 34 | 2027-08-20 | in 365 d | 2026-07-14 |
| A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT05648214Incidence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ALN-PNP, Placebo (PB) | Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 172 | 2027-08-10 | in 355 d | 2026-04-16 |
| A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsNCT07220772Percent change in Body Mass Index (BMI)Open-label · Treatment | Phase 3 | Recruiting | Drug: Mibavademab | Monogenic Obesity | 4 | 2027-06-18 | in 302 d | 2026-03-10 |
| An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney TransplantNCT05106387observationalIncidence of Adverse Events | — | Recruiting | Drug: Noninterventional | Chronic Kidney Disease (CKD) | 20 | 2027-06-14 | in 298 d | 2026-07-20 |
| A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsNCT07526116Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Not yet recruiting | Drug: REGN22044, Placebo | Healthy Volunteer | 64 | 2027-05-27 | in 280 d | 2026-04-13 |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)NCT06465329Major pathologic response (MPR) rate as determined by central blinded independent pathology review (BIPR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Cemiplimab, Platinum-based chemotherapy, REGN7075 | Non-Small Cell Lung Cancer | 120 | 2027-05-20 | in 273 d | 2026-07-08 |
| REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsNCT07213778Incidence of the composite endpoint of symptomatic VTE and all-cause deathRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: REGN7508, Acetylsalicylic Acid (ASA), Placebo | Symptomatic Venous Thromboembolism (VTE) | 2,000 | 2027-05-17 | in 270 d | 2026-08-19 |
| A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)NCT06836609Incidence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Drug: ALN-CIDEB, Placebo | Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | 132 | 2027-05-15 | in 268 d | 2026-07-08 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersNCT03564340Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapyNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer | 890 | 2027-05-10 | in 263 d | 2026-07-22 |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaNCT06572228Annualized severe asthma exacerbation rateRandomized · Quadruple-masked · Treatment | Phase 4 | Active, not recruiting | Drug: dupilumab, Matching Placebo, ICS/LABA | Asthma | 120 | 2027-04-24 | in 247 d | 2026-05-22 |
| Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) PatientsNCT06269133observationalReal-world response rate (rwRR) | — | Active, not recruiting | Drug: REGN2810 · Other: Platinum-doublet chemotherapy | Advanced Non-small Cell Lung Cancer | 1,000 | 2027-03-31 | in 223 d | 2026-05-08 |
| Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)NCT03428646observationalRegistry Assessment: Baseline Characteristics | — | Active, not recruiting | Drug: Dupilumab | Dermatitis, Atopic | 858 | 2027-03-30 | in 222 d | 2025-12-29 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabNCT04590326Incidence of Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 612 | 2027-03-25 | in 217 d | 2025-11-21 |
| Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)NCT04959448observationalBaseline Patient Characteristics | — | Active, not recruiting | Drug: DUPIXENT® | Chronic Rhinosinusitis With Nasal Polyposis | 717 | 2027-03-25 | in 217 d | 2026-07-13 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on HemodialysisNCT07759167Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Not yet recruiting | Drug: REGN9933, REGN7508, REGN9533, Heparin | End-Stage Kidney Disease (ESKD) | 36 | 2027-03-25 | in 217 d | 2026-08-12 |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)NCT06246916Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: fianlimab, cemiplimab, relatlimab+nivolumab | Melanoma | 560 | 2027-03-22 | in 214 d | 2026-08-19 |
| Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen AllergyNCT07309432Ocular itch score in participants receiving REGN5713-5715 compared to placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: REGN5713, REGN5715, Placebo | Allergic Conjunctivitis | 350 | 2027-02-28 | in 192 d | 2026-06-23 |
| Safety and Drug Concentrations of REGN20934 in Adults With Overweight or ObesityNCT07594093Occurrence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: REGN20934, Placebo | Overweight or Obesity | 90 | 2027-02-22 | in 186 d | 2026-07-07 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsNCT07015905Incidence of the composite endpoint of asymptomatic or symptomatic Venous Thromboembolism (VTE) [including VTE-related death]Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: REGN7508, Apixaban, Enoxaparin, Placebo | Venous Thromboembolism (VTE) | 2,000 | 2027-02-20 | in 184 d | 2026-07-13 |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationNCT07175428Incidence of any bleedingRandomized · Single-masked · Prevention | Phase 2 | Recruiting | Drug: REGN7508, REGN9933, Apixaban | Atrial Fibrillation (AF) | 1,200 | 2027-02-09 | in 173 d | 2026-08-05 |
| An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)NCT03936335observationalPrevalence of MCMs | — | Recruiting | Drug: dupilumab | Adverse Pregnancy Outcomes, Atopic Dermatitis | 3,930 | 2027-01-21 | in 154 d | 2025-08-03 |
| A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabNCT05259709Incidence and severity of treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: 89Zr˗DFO˗REGN5054, cemiplimab | Advanced Solid Tumor, Metastatic Solid Tumor | 50 | 2027-01-06 | in 139 d | 2025-09-11 |
| A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaNCT07477704Percent change in LDL-CRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Alirocumab | Hypercholesterolemia | 420 | 2026-12-29 | in 131 d | 2026-07-22 |
| A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy AdultsNCT06452771Incidence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: ALN-ANG3, Placebo (PB) | Healthy Volunteers With Hyperlipidemia | 59 | 2026-12-04 | in 106 d | 2026-02-20 |
| A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the BodyNCT06421636Change from baseline in Liver Iron Concentration (LIC) by R2* Magnetic Resonance Imaging (MRI)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: REGN7999, Placebo | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | 19 | 2026-12-03 | in 105 d | 2026-07-01 |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersNCT04626635The incidence of Dose-Limiting Toxicities (DLTs) during the DLT periodNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil | Advanced Solid Tumors | 548 | 2026-11-13 | in 85 d | 2026-07-02 |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Olatorepatide, Placebo | Overweight or Obesity | 120 | 2026-11-13 | in 85 d | 2026-06-17 |
| Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)NCT04515524observationalBinocular best-corrected visual acuity (BCVA) | — | Active, not recruiting | Other: Non-Interventional | Retinopathy of Prematurity | 100 | 2026-11-05 | in 77 d | 2026-03-27 |
| A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaNCT06190951Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR)Randomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo | Melanoma | 151 | 2026-11-02 | in 74 d | 2026-02-10 |
| A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentNCT05133531Percent change in lactate dehydrogenase (LDH)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Ravulizumab, Pozelimab, Cemdisiran, Eculizumab | Paroxysmal Nocturnal Hemoglobinuria | 202 | 2026-10-12 | in 53 d | 2026-04-30 |
| Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)NCT02612454Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visitNon-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Dupilumab | Atopic Dermatitis | 880 | 2026-10-07 | in 48 d | 2026-05-29 |
| A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samplesRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo | Resectable Non-small Cell Lung Cancer | 195 | 2026-08-24 | in 4 d | 2026-08-10 |
| A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement TherapyNCT05568459observationalAnnualized bleeding rate (ABR) | — | Active, not recruiting | Other: Non-Interventional | Hemophilia B | 11 | 2026-08-21 | in 1 d | 2026-08-07 |
| Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy AdultsNCT06669234Incidence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: ALN-F1202, Matching Placebo | Healthy Volunteer | 56 | 2026-07-30 | — | 2026-02-23 |
| A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryNCT05608291Relapse free survival (RSF)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Fianlimab, Cemiplimab, Pembrolizumab, Placebo | Melanoma | 1,564 | 2026-07-27 | — | 2026-07-06 |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesNCT03888105Objective Response Rate (ORR), as assessed by independent central reviewNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Odronextamab | B-cell Non-Hodgkin Lymphoma (B-NHL) | 515 | 2026-06-17actual | — | 2026-07-31 |
| A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098Incidence of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab | Obesity | 1,005 | 2026-05-06actual | — | 2026-07-21 |
| Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaNCT05352672Progression-free survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Fianlimab, Cemiplimab, Pembrolizumab, Placebo | Melanoma | 1,546 | 2026-03-12actual | — | 2026-04-22 |
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May HaveNCT05831176Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Dupilumab | Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis | 22 | 2026-02-23actual | — | 2026-07-01 |
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)NCT06491914Occurrence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Aflibercept 8 mg | Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | 1,118 | 2025-08-26actual | — | 2025-10-15 |
| A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)NCT05394116Number of new HO lesionsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Garetosmab, Placebo | Fibrodysplasia Ossificans Progressiva | 63 | 2025-07-17actual | — | 2026-07-17 |
| A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisNCT05070858Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Pozelimab + Cemdisiran, Cemdisiran, Pozelimab · Other: Placebo | Generalized Myasthenia Gravis | 288 | 2025-07-08actual | — | 2026-07-08 |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsNCT03916627Major pathologic response (MPR) at time of surgery for the NSCLC cohortsRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: cemiplimab, Platinum Doublet, fianlimab | Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma | 65 | 2025-03-31actual | — | 2026-04-06 |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)NCT07428369Occurrence of Treatment-Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 2/3 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: Linvoseltamab, Bortezomib, Lenalidomide, Daratumumab, Dexamethasone | Multiple Myeloma (MM) | 0 | 2038-05-21 | in 4,292 d | 2026-06-18 |
| A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 MutationsNCT06019481observationalHearing-related outcomes | — | Withdrawnsponsor's stated reason: Sponsor Decision | — | Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene, Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes | 0 | 2030-06-30 | in 1,410 d | 2025-05-15 |
| An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World SettingNCT06398080observationalMean prior treatment interval during the one-year period before study enrollment compared to the last assigned treatment interval during the study | — | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: aflibercept 8 mg | Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment | 0 | 2028-01-03 | in 501 d | 2024-11-25 |
| Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With DupilumabNCT07187089Improvement of ≥5 percentile in height-for-age percentile on the Centers for Disease Control and Prevention (CDC) growth chartOpen-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: dupilumab | Severe Atopic Dermatitis (AD) | 0 | 2027-12-23 | in 490 d | 2025-11-28 |
| A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsNCT07218770Occurrence of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Unfavorable benefit-risk assessment | Drug: REGN7041 | Active Noninfectious Uveitis Affecting the Posterior Segment | 1 | 2026-07-21actual | — | 2026-08-17 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)NCT06548100Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 3 | Completed | Drug: mibavademab | Generalized Lipodystrophy | 9 | 2026-07-09actual | — | 2026-07-29 |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)NCT06384820Pathological complete response (pCR) rate by blinded independent pathological review (BIPR)Randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Business Decision | Drug: cemiplimab, fianlimab | Cutaneous Squamous Cell Carcinoma | 0 | 2026-06-08 | — | 2024-07-26 |
| Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal WomenNCT06970405Incidence of treatment-emergent adverse events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: Garetosmab, Matching Placebo | Obesity | 0 | 2026-06-08 | — | 2025-09-17 |
| Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)NCT06593600Change in Heart Rate (HR) from supine to standing (DeltaHR)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: REGN7544, Placebo | Postural Orthostatic Tachycardia Syndrome (POTS) | 82 | 2026-05-06actual | — | 2026-07-21 |
| A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesNCT02651662Incidence of dose limiting toxicities (DLTs) of cemiplimab in combination with odronextamabNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: cemiplimab, odronextamab | Relapsed/Refractory Aggressive B-Cell Lymphoma | 105 | 2026-04-29actual | — | 2026-06-02 |
| Registry of Asthma Patients Initiating DUPIXENT®NCT04287621observationalDemography | — | Completed | Drug: DUPIXENT® | Asthma | 718 | 2026-04-27actual | — | 2026-06-04 |
| A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)NCT06299111Incidence of confirmed VTE per central reading center (CRC) reviewRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: REGN9933, REGN7508, Placebo | Venous Thromboembolism | 195 | 2026-03-27actual | — | 2026-04-13 |
| ALN-APOC3 in Adult Participants With DyslipidemiaNCT06784349Incidence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ALN-APOC3, Matching Placebo | Dyslipidemia | 32 | 2026-02-25actual | — | 2026-03-16 |
| A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced HypotensionNCT06608901Cumulative vasopressor doseRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: REGN7544, PB | Sepsis-Induced Hypotension | 76 | 2026-02-01actual | — | 2026-05-20 |
| Phase 1 Safety and Tolerability Study of REGN9533 in Healthy AdultsNCT06665828Incidence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN9533, Matching Placebo | Healthy Volunteer | 72 | 2026-01-29actual | — | 2026-02-06 |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell CarcinomaNCT03889912Incidence, nature, and severity of dose limiting toxicities (DLTs) (if any) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5Open-label · Treatment | Phase 1 | Completed | Drug: Cemiplimab | Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | 97 | 2025-11-13actual | — | 2026-01-21 |
| Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected PregnancyNCT04173442observationalRate of major structural defects | — | Completed | Drug: dupilumab | Atopic Dermatitis (AD), Asthma | 581 | 2025-11-04actual | — | 2026-03-04 |
| Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced CancerNCT04982224Dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN5093-M114, Cemiplimab | Advanced NSCLC | 30 | 2025-10-15actual | — | 2025-11-03 |
| REGN5381 in Adult Participants With Uncontrolled HypertensionNCT06833190Unattended Automated Office-Based Blood Pressure (AOBP) Systolic Blood Pressure (SBP)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN5381, Placebo | Uncontrolled Hypertension | 34 | 2025-10-15actual | — | 2025-10-23 |
| CemiplimAb Survivorship EpidemiologyNCT03836105observationalObjective response rate (ORR) | — | Completed | Drug: cemiplimab | Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | 287 | 2025-09-29actual | — | 2025-10-15 |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)NCT05169489Phase 1: Incidence of safety events including: adverse events (AEs), adverse events of special interest (AESIs), and dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: bbT369 | Diffuse Large B Cell Lymphoma (DLBCL) | 15 | 2025-09-19actual | — | 2025-10-21 |
| REGN5381 in Adult Participants With Heart Failure With Reduced Ejection FractionNCT06237309Change from baseline in circulating N-Terminal pro-Brain Natriuretic Peptide (NTproBNP)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN5381, Placebo | Heart Failure | 89 | 2025-09-17actual | — | 2026-01-14 |
| Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence StudyNCT07105228observationalIncidence of RV events | — | Completed | Drug: aflibercept 2mg | Retinal Vasculitis | 290,000 | 2025-08-30actual | — | 2025-10-10 |
| Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesNCT02290951Safety/overall frequency of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Odronextamab multiple dose levels, Odronextamab multiple dose levels | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 200 | 2025-08-21actual | — | 2025-10-10 |
| A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)NCT06769412observationalIncidence of RV events | — | Completed | Drug: aflibercept 2 mg | Retinal Vasculitis | 550,000 | 2025-08-15actual | — | 2025-10-29 |
| A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk FactorNCT06024408Incidence of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ALN-PNP, Placebo | Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor | 9 | 2025-07-07actual | — | 2025-07-31 |
| REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge PressureNCT05353166Incidence and severity of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: REGN5381, Matching Placebo | Heart Failure | 59 | 2025-06-02actual | — | 2025-06-11 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat AllergyNCT06602726Ocular itch scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: REGN1908, REGN1909, Placebo | Allergic Conjunctivitis | 64 | 2025-05-10actual | — | 2026-05-08 |
| First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)NCT04083534Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation periodOpen-label · Treatment | Phase 1/2 | Completed | Drug: REGN5459 | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | 43 | 2025-05-01actual | — | 2026-05-04 |
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen AllergyNCT06602739Ocular itch score in response to birch allergen challengeRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: REGN5713, REGN5715, Placebo | Allergic Conjunctivitis | 54 | 2025-04-23actual | — | 2026-04-21 |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540results2026-06-25Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab | Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer | 712 | 2025-04-18actual | — | 2026-06-25 |
| Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult ParticipantsNCT06444178Change in fecal hemoglobin content (FHC)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Aspirin, REGN9933, REGN7508, Rivaroxaban | Healthy Volunteers | 224 | 2025-04-07actual | — | 2025-07-16 |
| A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy AdultsNCT05923424Occurrence of all treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · TreatmentInformed Consent Form ↗ | Phase 1 | Completed | Drug: REGN17092, Matching Placebo | Healthy Volunteers | 40 | 2025-03-04actual | — | 2025-03-27 |
| Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerNCT03409614results2026-04-29Part 1: Overall Survival (OS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: REGN2810, REGN2810/chemo/ipi, Placebo · Other: Chemotherapy | Non-small Cell Lung Cancer | 789 | 2025-02-27actual | — | 2026-05-18 |
| A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult ParticipantsNCT06137482Incidence of treatment emergent adverse events (TEAE's) through the end of the study (EOS) visitRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN13335, Matching Placebo | Healthy Volunteers | 56 | 2025-02-11actual | — | 2025-03-19 |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor MalignanciesNCT04465487Incidence of dose-limited toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: REGN6569, Cemiplimab | Squamous Cell Carcinoma of Head and Neck | 38 | 2025-02-07actual | — | 2025-02-24 |
| A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult ParticipantsNCT06454630results2026-03-02Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN7508, Enoxaparin | Venous Thromboembolism | 179 | 2024-11-19actual | — | 2026-05-27 |
| Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema TrialNCT05590585results2026-01-02Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: dupilumab · Other: Topical emollient (moisturizer) | Moderate-to-Severe Atopic Dermatitis, Atopic Eczema | 124 | 2024-11-14actual | — | 2026-05-27 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerNCT04916002results2025-12-05Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision related to study drug supply | Drug: vidutolimod, cemiplimab | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma | 77 | 2024-10-31actual | — | 2026-06-09 |
| REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive TherapyNCT04409080Incidence of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: REGN7257 | Severe Aplastic Anemia (SAA) | 17 | 2024-10-17actual | — | 2026-06-22 |
| A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult ParticipantsNCT05603195Incidences of treatment-emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN7508 (IV), REGN7508 (SC), Matching Placebo (IV), Matching Placebo (SC) | Healthy Volunteer | 80 | 2024-09-17actual | — | 2024-10-01 |
| Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple MyelomaNCT05673967observationalProportion of patients exposed to each type of regimen by line of therapy (LOT) | — | Completed | Other: Non-Interventional | Relapsed and Refractory Multiple Myeloma (RRMM) | 62 | 2024-09-12actual | — | 2025-04-25 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaNCT04695977results2025-09-05Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Business Decision | Drug: CMP-001, Nivolumab | Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma | 20 | 2024-07-22actual | — | 2026-06-15 |
| A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult ParticipantsNCT05970718Incidence of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN7544, Matching Placebo | Healthy Volunteers | 80 | 2024-07-22actual | — | 2024-08-12 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidNCT04206553results2026-03-06Percent of Participants Achieving Sustained Remission at Week 36Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: dupilumab, Matching Placebo, Oral corticosteroids (OCS) | Bullous Pemphigoid | 106 | 2024-07-12actual | — | 2026-06-18 |
| Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)NCT05989126results2026-05-28Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFSOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: aflibercept 8 mg PFS | Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) | 35 | 2024-05-31actual | — | 2026-05-28 |
| T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten ChallengeNCT04614571Change from Baseline in small intestine TCR repertoireOpen-label · Other | Not applicable | Completed | Dietary supplement: Gluten Powder | Celiac Disease | 24 | 2024-05-30actual | — | 2024-06-27 |
| A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult ParticipantsNCT05618808results2025-07-16Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN9933, Enoxaparin, Apixiban | Venous Thromboembolism | 373 | 2024-05-27actual | — | 2025-08-29 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced CancersNCT03005782Rate of dose limiting toxicities (Dose Escalation Phase)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: REGN3767, cemiplimab | Malignancies | 333 | 2024-04-02actual | — | 2024-05-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive ParticipantsNCT05291546Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN9035, REGN5381 · Other: Placebo | Healthy Volunteers | 93 | 2024-04-02actual | — | 2024-04-15 |
| CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaNCT04698187results2025-04-02Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: CMP-001, Nivolumab | Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma | 44 | 2024-02-05actual | — | 2025-06-11 |
| CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT04633278results2025-04-08Confirmed Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: CMP-001, Pembrolizumab | Squamous Cell Carcinoma of Head and Neck | 24 | 2024-01-19actual | — | 2025-05-11 |
| A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)NCT05088460results2025-07-02Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: REGN4461, Matching Placebo | Familial Partial Lipodystrophy, Metabolic Abnormalities | 20 | 2023-12-13actual | — | 2025-10-16 |
| Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical StudyNCT02520245Overall survival, from the first dose of study drug administered in the parent REGN2810 clinical study to death or date of last censoringOpen-label · Treatment | Phase 1 | Withdrawn | Drug: REGN2810 | Advanced Malignancies | 0 | Nov 2023 | — | 2016-11-07 |
| Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell CarcinomaNCT02760498results2024-12-11Overall Response Rate (ORR) by Independent Central ReviewNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma | 432 | 2023-10-18actual | — | 2025-05-28 |
| Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular LymphomaNCT05338879observationalObjective response rate | — | Completed | Other: Non-Interventional | Relapsed/Refractory Follicular Lymphoma | 247 | 2023-10-05actual | — | 2023-10-18 |
| Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT05338892observationalObjective response rate | — | Completed | Other: Non-Interventional | Diffuse Large B-Cell Lymphoma | 595 | 2023-10-05actual | — | 2023-10-19 |
| A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)NCT06064656observationalDemographic characteristics | — | Completed | Other: Non-Interventional | Fibrodysplasia Ossificans Progressiva (FOP) | 131 | 2023-09-22actual | — | 2025-07-03 |
| A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy ParticipantsNCT05481333Incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with REGN7999 or placeboRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN7999, Placebo | Healthy | 64 | 2023-08-29actual | — | 2024-07-24 |
| Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult ParticipantsNCT05430919results2024-11-19Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at Day 29Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN5713, REGN5714, REGN5715 · Other: Placebo | Allergic Rhinitis, Conjunctivitis | 217 | 2023-07-31actual | — | 2024-11-19 |
| Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)NCT04442269results2024-08-21Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: dupilumab, Placebo | Allergic Bronchopulmonary Aspergillosis | 62 | 2023-07-27actual | — | 2025-04-04 |
| A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With AsthmaNCT04203797results2024-04-18Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: dupilumab, Matching placebo | Asthma | 40 | 2023-07-15actual | — | 2024-04-18 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaNCT05131204results2024-09-19Percent Change in Lactate Dehydrogenase (LDH) From Baseline to Week 36Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision not related to efficacy or safety. | Drug: Cemdisiran, Eculizumab, Pozelimab, Ravulizumab | Paroxysmal Nocturnal Hemoglobinuria | 3 | 2023-07-12actual | — | 2025-04-08 |
| A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult ParticipantsNCT05505448Occurrence and severity of all treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN14284, Matching Placebo | Healthy | 48 | 2023-05-30actual | — | 2023-07-27 |
| Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line ChemotherapyNCT04646005results2024-09-19Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Cemiplimab · Biological: ISA101b | Cervical Cancer | 113 | 2023-05-22actual | — | 2025-09-08 |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent GliomaNCT03690869results2024-10-09Number of Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: cemiplimab (monotherapy), cemiplimab (maintenance) · Radiation: Conventional or hypofractionated, Re-irradiation | Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma | 57 | 2023-05-10actual | — | 2025-04-08 |
| Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaNCT03409744results2024-04-30Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: evinacumab | Homozygous Familial Hypercholesterolemia | 116 | 2023-04-13actual | — | 2025-04-08 |
| Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult ParticipantsNCT05546957Change from baseline in fecal hemoglobin content as measured by HemoQuant during the second week of exposure to study medicationRandomized · Open-label · Screening | Not applicable | Completed | Drug: Aspirin, rivaroxaban low dose, rivaroxaban high dose | Healthy Volunteer | 60 | 2023-04-06actual | — | 2023-05-24 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy VolunteersNCT05102136Incidence and severity of treatment emergent adverse events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN9933, Placebo | Healthy Volunteers | 56 | 2023-04-04actual | — | 2023-05-03 |
| Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic DermatitisNCT04287608observationalBaseline Ophthalmologist Diagnosis | — | Completed | Drug: dupilumab | Conjunctivitis, Atopic Dermatitis | 50 | 2023-03-29actual | — | 2023-04-28 |
| Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid TumorsNCT02744287Dose Limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Due to a Dose Limiting Toxicity. | Biological: BPX-601 · Drug: Rimiducid | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | 52 | 2023-03-14actual | — | 2026-02-23 |
| Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic DermatitisNCT05203380observationalProportion of AD patients with a Conner's CPT-3 d' T-score ≥ 60 | — | Completed | Drug: dupilumab | Moderate-to-severe Atopic Dermatitis | 45 | 2023-03-10actual | — | 2023-09-08 |
| Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute PancreatitisNCT04863014results2024-05-22Percentage of Participants With at Least One Positively Adjudicated Acute Pancreatitis (AP) EpisodeRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: evinacumab · Other: Placebo | Hypertriglyceridemia | 21 | 2023-02-15actual | — | 2024-05-22 |
| Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19NCT05293678Occurrence and severity of all treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN15160 (IV), Matching Placebo (IV), REGN15160 (SC), Matching Placebo (SC) | Healthy | 104 | 2023-01-26actual | — | 2023-02-23 |
| A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatNCT04981717results2024-06-11Daily Combined Symptom and Medication Score (CSMS) Averaged Over Last 12 Weeks of the Treatment Period in Patients Who Receive REGN1908-1909 Versus PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Lack of efficacy | Drug: REGN1908-1909, Matching Placebo | Allergic Rhinitis Due to Cat Allergy | 446 | 2023-01-04actual | — | 2024-06-11 |
| A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022NCT05791695observationalFrequency of patients receiving aflibercept injections | — | Completed | Other: Non Applicable | Intraocular Inflammation, Suspected Endophthalmitis | 155,413 | 2022-12-30actual | — | 2023-12-01 |
| Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaNCT04373083Progression-free survival (PFS) at 1 yearRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Business Decision | Drug: Cemiplimab · Radiation: Involved-site radiotherapy (IS-RT) | Hodgkin Lymphoma | 0 | 2022-12-20 | — | 2021-01-15 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult HumansNCT04506645Incidence of Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN5381 · Other: Placebo | Healthy | 90 | 2022-12-14actual | — | 2022-12-20 |
| Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyNCT02680184Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Given in Combination With PembrolizumabNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CMP-001, Pembrolizumab | Melanoma | 199 | 2022-12-06actual | — | 2025-07-04 |
| COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult VolunteersNCT04852978results2024-08-2050% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine | Healthy, Chronic Stable Illness | 295 | 2022-11-21actual | — | 2025-10-20 |
| Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)NCT05423327Genotype frequencies of rs72613567 in Hydroxysteroid 17β dehydrogenase 13 (HSD17B13)Open-label · Screening | Not applicable | Terminatedsponsor's stated reason: Sponsor Decision | Procedure: No Intervention | Non-alcoholic Steatohepatitis (NASH) | 5,311 | 2022-10-27actual | — | 2023-03-17 |
| Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyNCT04811716results2025-01-16Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | 24 | 2022-10-25actual | — | 2025-04-08 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)NCT04417894results2023-12-22Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: dupilumab, Placebo | Moderate to Severe Atopic Hand and Foot Dermatitis | 133 | 2022-08-31actual | — | 2023-12-22 |
| Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of PrematurityNCT04101721results2023-07-20Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological AgeRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: aflibercept · Procedure: laser photocoagulation | Retinopathy of Prematurity | 127 | 2022-08-18actual | — | 2023-07-20 |
| COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe DiseaseNCT05081388results2024-04-26Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: REGN14256, imdevimab, casirivimab + imdevimab, Placebo | SARS-CoV-2 | 25 | 2022-06-30actual | — | 2025-10-28 |
| Open-label Study of Dupilumab in Patients With Atopic DermatitisNCT01949311results2023-10-17Number of Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab | Atopic Dermatitis | 2,733 | 2022-06-27actual | — | 2023-10-17 |
| A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy VolunteersNCT04940364Concentrations of pozelimab in serum over timeNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Pozelimab, Cemdisiran | Healthy | 30 | 2022-06-22actual | — | 2022-07-06 |
| COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19NCT05092581Concentrations of casirivimab+imdevimab in serum over timeOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Emerging SARS-CoV-2 variants impacting susceptibility to study drug | Drug: casirivimab+imdevimab | COVID-19 | 2 | 2022-06-09actual | — | 2025-10-14 |
| COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult VolunteersNCT05181683Targeted grade ≥3 treatment-emergent adverse events (TEAEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Casirivimab+Imdevimab | Healthy, Chronic Stable Illness | 45 | 2022-06-03actual | — | 2025-10-14 |
| Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)NCT04394351results2024-08-27Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Matching Placebo | Eosinophilic Esophagitis (EoE) | 102 | 2022-06-02actual | — | 2025-10-27 |
| COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of AgeNCT04992273results2023-03-06Concentrations of Casirivimab+Imdevimab in Serum Over Time.Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Emerging SARS-CoV-2 variants impacting susceptibility to study drug | Drug: casirivimab+imdevimab | COVID-19 | 7 | 2022-06-01actual | — | 2025-10-20 |
| Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseNCT04429503results2023-11-21Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: aflibercept, High-dose aflibercept | Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 660 | 2022-05-30actual | — | 2025-08-08 |
| A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and AdultsNCT05074433results2023-07-24Cumulative Incidence of Symptomatic (Broad Term), RT-PCR-confirmed SARS-CoV-2 Infection Cases During the EAPRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Emerging SARS-CoV2 variants impacting susceptibility to study drug | Drug: casirivimab+imdevimab, Placebo | Immunocompromised | 66 | 2022-05-18actual | — | 2025-10-20 |
| Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab TherapyNCT04888507results2025-06-25OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | 6 | 2022-05-05actual | — | 2025-08-29 |
| REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.NCT04162470results2023-06-12Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Business Decision | Drug: REGN3918 | Paroxysmal Nocturnal Hemoglobinuria | 24 | 2022-04-07actual | — | 2023-06-12 |
| Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)NCT04577820Incidence and severity of treatment-emergent adverse event (TEAEs)Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned | Drug: garetosmab | Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO) | 0 | 2022-03-01 | — | 2021-11-01 |
| Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial HypercholesterolemiaNCT04233918results2023-06-07Part A: Maximum Observed Serum Concentration (Cmax) of EvinacumabOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Evinacumab | Homozygous Familial Hypercholesterolemia | 20 | 2022-01-31actual | — | 2024-07-16 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19NCT04425629results2023-12-21Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3]Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Terminatedsponsor's stated reason: Emerging SARS-CoV-2 variants impacting susceptibility to study drug | Drug: casirivimab+imdevimab combination therapy | COVID-19 | 10,078 | 2022-01-21actual | — | 2023-12-21 |
| Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyNCT04159415results2025-02-25Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Low-Dose REGN4461, High-dose REGN4461 | Generalized Lipodystrophy | 16 | 2022-01-05actual | — | 2026-06-15 |
| Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell CarcinomaNCT04154943results2023-02-08Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology ReviewOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Cemiplimab | Cutaneous Squamous Cell Carcinoma | 79 | 2021-12-01actual | — | 2025-12-23 |
| Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19NCT04519437Incidence of adverse event of special interests (AESIs) that occur within 4 days of study drug administrationRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN10933+REGN10987, Placebo | Healthy, Chronic Stable Illness | 974 | 2021-11-22actual | — | 2022-01-26 |
| Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)NCT04209634results2023-10-30Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Pozelimab | CD55-deficient Protein-losing Enteropathy, CHAPLE | 10 | 2021-11-09actual | — | 2025-08-29 |
| A Study of REGN2810 and Ipilimumab in Patients With Lung CancerNCT03430063results2022-11-03Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor CellsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business decision | Drug: SDREGN2810, SDREGN2810/ipi, HDREGN2810 | Advanced Non-Small Cell Lung Carcinoma | 28 | 2021-10-27actual | — | 2022-11-03 |
| COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR AssayNCT04452318results2023-05-15Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAPRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Completed | Drug: REGN10933 + REGN10987, Placebo | Healthy Participants | 3,303 | 2021-10-04actual | — | 2023-05-15 |
| Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)NCT03633617results2022-12-28Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Part A/Part C ↗ · Statistical Analysis Plan: Part B/Part C ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo | Eosinophilic Esophagitis | 321 | 2021-09-09actual | — | 2023-06-28 |
| Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic RhinitisNCT04709575results2022-10-27Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: REGN5713, REGN5714, REGN5715, Placebo | Allergic Rhinitis, Conjunctivitis | 353 | 2021-08-24actual | — | 2022-10-27 |
| REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung CancerNCT03515629results2022-11-16Progression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) AssessmentsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Business decision | Drug: REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab | Non-small Cell Lung Cancer | 5 | 2021-07-29actual | — | 2022-11-16 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult VolunteersNCT04601844Incidence and severity of treatment emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Pozelimab, Cemdisiran | Healthy | 19 | 2021-07-23actual | — | 2021-11-12 |
| Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)NCT03346434results2022-07-28Part A: Maximum Observed Serum Concentration (Cmax) of Functional DupilumabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Dupilumab, Matching placebo | Dermatitis, Atopic | 202 | 2021-07-08actual | — | 2022-07-28 |
| Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive MalignanciesNCT03746704Incidence and severity of treatment-emergent adverse events (TEAEs)Open-label · Basic science | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: 89Zr˗DFO˗REGN3504 | Advanced PD-L1 Positive Malignancies | 2 | 2021-07-08actual | — | 2022-02-23 |
| Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaNCT03084640Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Administered SC and Given in Combination With PembrolizumabNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CMP-001, Pembrolizumab, CMP-001 | Malignant Melanoma | 30 | 2021-07-02actual | — | 2022-08-03 |
| Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT03946748results2023-06-26Percentage of Participants Who Achieved Adequate Control of Intravascular HemolysisOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN3918 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 24 | 2021-06-09actual | — | 2023-06-26 |
| Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy VolunteersNCT04616079Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN6490, Placebo | Healthy Volunteer | 57 | 2021-06-01actual | — | 2021-11-11 |
| Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult VolunteersNCT04616105Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN6490, Placebo | Healthy Volunteer | 19 | 2021-05-28actual | — | 2021-11-11 |
| PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor TherapyNCT03132636results2022-07-26Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: cemiplimab | Carcinoma, Basal Cell | 138 | 2021-05-20actual | — | 2025-04-08 |
| Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular DegenerationNCT04126317results2023-08-14Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: aflibercept, High-dose aflibercept | Neovascular (Wet) Age-Related Macular Degeneration | 106 | 2021-05-14actual | — | 2023-08-14 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19NCT04426695results2022-07-25Pooled Analysis (Phase 3 [Cohort 1] and Phase 2 [Cohort 1A]): Time-weighted Average (TWA) Change in Viral Load in Nasopharyngeal (NP) Samples Based on Seronegative mFASRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: REGN10933+REGN10987 combination therapy, Placebo | COVID-19 | 2,252 | 2021-05-07actual | — | 2023-01-27 |
| Study of Cemiplimab in Adults With Cervical CancerNCT03257267results2022-04-06Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cemiplimab, Investigator Choice (IC) Chemotherapy | Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer | 608 | 2021-03-15actual | — | 2025-04-08 |
| Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult ParticipantsNCT04491838Assess the time of the last positive concentration (AUClast) pharmacokinetic (PK) profile of pozelimab in Process ARandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Pozelimab | Healthy Volunteer | 40 | 2021-03-05actual | — | 2021-03-23 |
| COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 InfectionNCT04666441results2022-04-08Time-Weighted Average Daily Change From Day 1 in Viral Load in NP Swab SamplesRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN10933+REGN10987 combination therapy, Placebo | COVID-19 | 1,149 | 2021-03-04actual | — | 2022-04-08 |
| Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut AllergyNCT03793608results2022-05-19Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Dupilumab | Peanut Allergy | 25 | 2021-02-19actual | — | 2022-05-19 |
| Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or HipNCT02683239results2023-10-13Number of Participants With Any Treatment-Emergent Adverse Event (TEAE)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Fasinumab, Placebo | Osteoarthritis of the Knee or Hip | 5,331 | 2020-12-01actual | — | 2023-10-13 |
| Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)NCT03682770results2024-02-07Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Dupilumab, Placebo matching dupilumab, AR101 | Peanut Allergy | 148 | 2020-10-16actual | — | 2024-02-07 |
| Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance StudyNCT03379558observationalRate of major structural birth defects | — | Terminatedsponsor's stated reason: (due to change in the post-marketing requirement to assess alirocumab during pregnancy) | Drug: ALIROCUMAB SAR236553 (REGN727) | Hypercholesterolemia | 37 | 2020-09-04actual | — | 2020-11-23 |
| Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisNCT03710941Percent change in total lean mass as measured by dual-energy X-ray absorptiometry (DXA)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The study was withdrawn due to an internal decision | Drug: REGN2477+REGN1033, Matching placebo | Sporadic Inclusion Body Myositis | 0 | 2020-08-27 | — | 2019-04-29 |
| Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and HipNCT03949673results2023-10-17Number of Participants by Degree of Synovial Lymphocytic InflammationOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Lack of enrollment | Drug: Fasinumab, Naproxen, Diclofenac, Celecoxib, Placebo | Osteoarthritis, Knee, Osteoarthritis, Hip | 23 | 2020-08-25actual | — | 2023-10-17 |
| Study to Evaluate an Aflibercept (EYLEA®) Prefilled SyringeNCT03767738results2021-09-16Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Intravitreal Aflibercept Injection (IAI) | Chorioretinal Vascular Disease | 65 | 2020-08-19actual | — | 2021-09-16 |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19NCT04315298results2021-09-23Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2/3 | Completed | Drug: Sarilumab, Placebo | COVID-19 | 1,912 | 2020-07-24actual | — | 2021-09-23 |
| Study of Evinacumab (REGN1500) in Participants With Persistent HypercholesterolemiaNCT03175367results2023-02-10Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Evinacumab, Matching placebo · Other: Background Lipid Modifying Therapy (LMT) | Hypercholesterolemia | 272 | 2020-05-22actual | — | 2023-02-10 |
| A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the KneeNCT03956550results2021-07-01Change From Baseline to Week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee | Drug: REGN5069, Matching Placebo | Osteoarthritis of the Knee, Pain | 259 | 2020-05-01actual | — | 2021-07-01 |
| Long Term Safety Study of PRALUENTNCT03694197results2021-06-15Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 WeeksOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies. | Drug: Praluent | Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia | 1,389 | 2020-04-08actual | — | 2021-06-15 |
| Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult ParticipantsNCT03969849Incidence and severity of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN5713-5714-5715, Matching placebo | Healthy Volunteers, Birch Pollen Allergy | 96 | 2020-03-27actual | — | 2020-04-28 |
| Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic DermatitisNCT03736967results2021-11-01Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy | Drug: REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo | Atopic Dermatitis | 206 | 2020-03-13actual | — | 2021-11-01 |
| Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisNCT03738423results2022-06-10Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy | Drug: REGN3500, REGN3500-Matching Placebo | Atopic Dermatitis | 129 | 2020-03-13actual | — | 2022-06-10 |
| Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to PlaceboNCT02957682results2021-05-07Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Praluent (Alirocumab), Placebo | Hypercholesterolemia | 2,176 | 2020-03-05actual | — | 2021-05-07 |
| Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or KneeNCT03691974results2023-03-01Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Fasinumab · Other: Placebo | Osteoarthritis, Knee, Osteoarthritis, Hip | 180 | 2020-01-30actual | — | 2023-03-01 |
| A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy VolunteersNCT03530514Number of treatment-emergent adverse events (TEAEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: REGN4461, Placebo | Healthy Volunteers | 113 | 2020-01-27actual | — | 2020-03-09 |
| To Assess the Patients' Ability to Self-Administer FasinumabNCT03491904Percentage of device-associated product technical failure (PTF) for the AI based on the total number of fasinumab injections administered by patients/caregivers in an unsupervised settingRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Fasinumab AI, Fasinumab PFS | Osteoarthritis, Knee, Osteoarthritis, Hip | 100 | 2020-01-15actual | — | 2021-03-03 |
| Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen ChallengeNCT03838731results2021-07-01Time to Early Asthmatic Response (EAR) Upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit (EEU) on Day 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN1908-1909, Placebo | Cat Allergy, Mild Asthma | 56 | 2019-12-21actual | — | 2021-07-01 |
| Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute PancreatitisNCT03452228results2023-02-16Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 ParticipantsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: evinacumab, Placebo | Severe Hypertriglyceridemia (sHTG) | 52 | 2019-12-17actual | — | 2023-02-16 |
| Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipNCT03304379results2023-02-24Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to PlaceboRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Fasinumab, Matching placebo · Other: Diclofenac, Celecoxib | Osteoarthritis, Knee, Osteoarthritis, Hip | 1,650 | 2019-12-13actual | — | 2023-02-24 |
| Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerNCT03438318Part A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CMP-001, Atezolizumab · Radiation: Radiation Therapy | Non Small Cell Lung Cancer | 29 | 2019-12-11actual | — | 2022-08-03 |
| Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03580694Rate of dose limiting toxicities (DLTs) during the dose escalation phaseNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Program reprioritization | Drug: REGN4659, Cemiplimab | Carcinoma, Non-Small-Cell Lung | 17 | 2019-12-04actual | — | 2020-03-13 |
| Study of REGN2810 (Anti-PD-1) in Patients With Advanced MalignanciesNCT02383212Incidence of Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cemiplimab, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed · Radiation: Hypofractionated radiotherapy | Advanced Cancer, Advanced Malignancies | 398 | 2019-11-18actual | — | 2020-01-27 |
| Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy VolunteersNCT03645746Incidence and severity of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: REGN5069, Placebo | Healthy Volunteer | 56 | 2019-09-30actual | — | 2019-11-26 |
| Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)NCT03156621results2021-06-29Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Alirocumab, Placebo | Homozygous Familial Hypercholesterolemia | 69 | 2019-09-27actual | — | 2021-06-29 |
| A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans ProgressivaNCT03188666results2022-12-02Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN2477, Matching placebo | Fibrodysplasia Ossificans Progressiva | 44 | 2019-09-16actual | — | 2022-12-02 |
| A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipNCT03161093results2022-11-14Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With PlaceboRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo | Osteoarthritis, Knee, Osteoarthritis, Hip | 3,307 | 2019-09-09actual | — | 2022-11-14 |
| An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)NCT03198130Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline.Open-label · Treatment | Phase 1 | Completed | Drug: REGN2810 | Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck, Metastatic Squamous Cell Carcinoma of Head, Metastatic Squamous Cell Carcinoma Neck | 33 | 2019-06-27actual | — | 2020-03-19 |
| Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)NCT03345914results2020-08-13Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Matching Placebo · Other: Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers | Dermatitis, Atopic | 367 | 2019-06-20actual | — | 2020-08-13 |
| Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaNCT03399786results2021-05-18Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: evinacumab, Placebo | Homozygous Familial Hypercholesterolemia | 65 | 2019-06-10actual | — | 2021-05-18 |
| Dupilumab As An Adjunct For Subcutaneous Grass ImmunotherapyNCT03558997results2020-05-28Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT | Allergic Rhinitis | 103 | 2019-05-14actual | — | 2020-05-28 |
| Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult MenNCT02943239Incidence and severity of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: REGN1033, REGN2477 · Other: Placebo | Healthy Volunteers | 82 | 2019-04-30actual | — | 2024-08-09 |
| Study of REGN3500 and Dupilumab in Patients With AsthmaNCT03112577Difference in bronchial allergen challenge (BAC)-induced changes in sputum inflammatory markers in individuals treated with REGN3500, dupilumab and the combination of REGN3500 plus dupilumab or placeboRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN3500, Dupilumab, Placebo, Fluticasone propionate | Asthma, Allergic | 32 | 2019-03-20actual | — | 2020-01-18 |
| An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)NCT03002376Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baselineOpen-label · Treatment | Phase 1 | Completed | Drug: REGN2810 | Melanoma | 47 | 2019-03-05actual | — | 2020-04-20 |
| Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy VolunteersNCT03115996Incidence of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: REGN3918, Placebo | Healthy Volunteers | 56 | 2018-08-31actual | — | 2018-09-26 |
| Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate AsthmaNCT02999711Incidence of treatment emergent adverse events (TEAEs) after repeat subcutaneous administrationRandomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: REGN3500, Placebo | Asthma, Moderate Asthma | 23 | 2018-08-30actual | — | 2018-12-12 |
| Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)NCT02718326results2019-11-21Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 GroupsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Intravitreal aflibercept injection [IAI], Sham | Nonproliferative Diabetic Retinopathy | 402 | 2018-08-06actual | — | 2020-07-30 |
| Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy VolunteersNCT03146416Incidence of Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: Evinacumab, Placebo | Healthy Volunteers | 96 | 2018-06-14actual | — | 2018-06-25 |
| Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or KneeNCT03285646results2021-06-30Change From Baseline to Week 16 in the Average Daily Low Back Pain Intensity (LBPI) Numeric Rating Scale (NRS) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Due to implementation of an urgent safety measure, enrollment and dosing in R475-PN-1612 was stopped; enrolled participants entered the 20-week safety follow-up | Drug: Fasinumab, Placebo | Chronic Low Back Pain, Osteoarthritis | 63 | 2018-05-05actual | — | 2021-06-30 |
| Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic DermatitisNCT03054428results2019-07-23Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo | Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic | 251 | 2018-04-04actual | — | 2019-07-23 |
| Study of Dupilumab Auto-injector Device When Used by Patients With Atopic DermatitisNCT03050151Number of validated AI device-associated product technical failures (PTFs) during the treatment period divided by total number of actual injectionsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Dupilumab · Device: Auto-injector Device, Prefilled syringe | Atopic Disorders, Eczema, Atopic | 176 | 2017-11-14actual | — | 2018-08-01 |
| Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal InjectionNCT02713204results2019-05-07Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN910-3, Intravitreal Aflibercept Injection (IAI) | Neovascular Age-Related Macular Degeneration | 365 | 2017-10-03actual | — | 2019-05-07 |
| Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular EdemaNCT02712008results2018-10-03Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: REGN910-3, Intravitreal Aflibercept Injection (IAI) | Diabetic Macular Edema | 302 | 2017-07-10actual | — | 2018-10-03 |
| Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm InfantsNCT02325791results2018-11-06Part A: Serum Concentration of Suptavumab Over TimeRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Part A ↗ · Statistical Analysis Plan: Part B ↗ | Phase 3 | Completed | Drug: Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses | Respiratory Syncytial Virus Infections | 1,177 | 2017-07-05actual | — | 2018-11-06 |
| A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult SubjectsNCT02958436The incidence and severity of treatment-emergent adverse events in subjects treated with REGN3500Randomized · Triple-masked · Other | Phase 1 | Completed | Drug: REGN3500, Placebo | Healthy Volunteers | 40 | 2017-06-18actual | — | 2017-11-08 |
| Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult VolunteersNCT02777151Incidence and severity of TEAEs through the end of the study visit in subjects treated with REGN3470-3471-3479 in a fixed dose combinationRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: REGN3470-3471-3479, Placebo | Healthy Volunteers | 24 | 2017-04-26actual | — | 2018-02-05 |
| Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)NCT02379052results2020-02-28Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Dupilumab, Placebo | Eosinophilic Esophagitis | 47 | 2017-02-17actual | — | 2020-02-28 |
| A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back PainNCT02620020results2019-08-01Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Fasinumab, placebo | Low Back Pain | 563 | 2017-02-03actual | — | 2020-06-16 |
| A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477NCT02870400Treatment emergent adverse events (TEAEs) through day 113 in participants treated with REGN2477Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: REGN2477, Placebo | Healthy Volunteers | 41 | 2017-01-12actual | — | 2017-02-20 |
| A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically AdvisableNCT02755649results2020-08-20Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Dupilumab, Matching Placebo | Atopic Dermatitis | 325 | 2017-01-04actual | — | 2020-08-20 |
| Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)NCT01576484results2020-08-05Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to DeathNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Alirocumab, Placebo Matched to Alirocumab | Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia | 58 | 2016-12-22actual | — | 2020-08-05 |
| Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)NCT02265952results2019-12-09Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study PeriodOpen-label · Treatment | Phase 2 | Completed | Drug: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | Homozygous Familial Hypercholesterolemia | 9 | 2016-11-21actual | — | 2019-12-09 |
| Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy SubjectsNCT02828397Serum REGN2222 concentration-time curve (AUC)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: REGN2222 | Healthy Volunteers | 28 | Sep 2016actual | — | 2016-11-04 |
| Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)NCT02418754results2020-10-26Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12Randomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: No additional efficacy seen with REGN2176-3 over aflibercept alone | Drug: REGN2176-3, Intravitreal Aflibercept Injection (IAI) | Neovascular Age-Related Macular Degeneration | 505 | 2016-08-17actual | — | 2020-10-26 |
| A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)NCT02395133results2018-10-17Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dupilumab, Placebo | Atopic Dermatitis | 422 | Jul 2016actual | — | 2020-03-11 |
| Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)NCT02647086Ratio of Area Under Curve last (AUClast) and maximum concentration (Cmax) for Cytochrome P450 substrates from pre-dupilumab administration at baseline (period 1, day 1)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol | Atopic Dermatitis | 14 | Jul 2016actual | — | 2016-08-22 |
| Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy SubjectsNCT02741739Serum REGN1033 concentration-time curve (AUC)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: REGN1033 | Healthy | 28 | Apr 2016actual | — | 2016-10-14 |
| A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)NCT02407756results2020-10-05Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single AdministrationNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Dupilumab | Atopic Dermatitis | 78 | 2016-03-31actual | — | 2020-11-27 |
| Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or HipNCT02447276The primary endpoint in the study is the change from baseline to week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale score.Randomized · Triple-masked · Treatment | Phase 2/3 | Completed | Drug: REGN475, Placebo | Osteoarthritis, Knee, Osteoarthritis, Hip | 421 | Mar 2016actual | — | 2017-03-27 |
| Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian SubjectsNCT02516618The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with fasinumab or placebo.Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: Fasinumab, Placebo | Healthy Volunteers | 72 | Feb 2016actual | — | 2016-05-12 |
| Study to Assess the Safety and Tolerability of Single Doses of REGN1500NCT01749878SafetyRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: REGN1500, placebo | Hypertriglyceridemia | 99 | Jan 2016actual | — | 2016-05-12 |
| Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyNCT02326220results2020-05-01Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Alirocumab | Heterozygous Familial Hypercholesterolemia | 62 | 2016-01-31actual | — | 2020-05-01 |
| Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult ParticipantsNCT02127801Change in allergic symptom scale scoreRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: REGN1908-1909, placebo | Allergy | 74 | 2015-12-31actual | — | 2020-12-16 |
| Study of REGN1193 in Patients With Type 2 Diabetes MellitusNCT02284425Incidence and severity of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminated | Drug: REGN1193, Placebo | Diabetes Mellitus, Type 2 | 72 | Dec 2015actual | — | 2016-05-12 |
| Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisNCT02277743results2017-11-21Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dupilumab, Placebo (for Dupilumab) | Dermatitis, Atopic | 671 | Nov 2015actual | — | 2017-11-21 |
| Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)NCT01997164Incidence of treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI) | Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | 20 | Oct 2015actual | — | 2016-01-12 |
| Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisNCT02277769results2017-10-16Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dupilumab, Placebo (for Dupilumab) | Dermatitis, Atopic | 708 | 2015-10-31actual | — | 2020-06-02 |
| Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)NCT01722045results2017-12-22Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF)Open-label · Treatment | Phase 4 | Completed | Drug: Intravitreal Aflibercept Injection (IAI) | Age - Related Macular Degeneration (AMD) | 154 | Sep 2015actual | — | 2017-12-22 |
| Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500NCT02107872SafetyRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN1500, placebo | Metabolic Disorders | 55 | Sep 2015actual | — | 2015-09-30 |
| Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)NCT02210780results2020-05-07Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Dupilumab, Placebo | Atopic Dermatitis | 194 | 2015-09-15actual | — | 2020-05-07 |
| Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic DermatitisNCT02260986results2017-10-17Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dupilumab, Placebo (for Dupilumab) · Other: Topical Corticosteroid (TCS) | Atopic Dermatitis | 740 | Aug 2015actual | — | 2017-10-17 |
| Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)NCT02097524PD parametersRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Sarilumab, Tocilizumab | Rheumatoid Arthritis | 105 | Apr 2015actual | — | 2015-05-05 |
| Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult VolunteersNCT02121080The incidence and severity of treatment-emergent adverse events (TEAEs) in participants treated with REGN2222 or placebo.Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: REGN2222(SAR438584), placebo | Healthy Volunteers | 132 | Feb 2015actual | — | 2015-03-11 |
| Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of CancerNCT01727869The primary objective of the study is to characterize the safety profile of REGN1400 alone and in combination with erlotinib or cetuximabNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: REGN1400, Erlotinib, Cetuximab | Cancer | 56 | Jan 2015actual | — | 2015-04-06 |
| An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193NCT01933763Number of TEAEsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN1193 · Other: Placebo | Healthy Volunteers | 56 | Jan 2015actual | — | 2015-03-13 |
| Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With SarcopeniaNCT01963598Percent change in total lean body massRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: REGN1033 (SAR391786), placebo | Sarcopenia | 253 | Jan 2015actual | — | 2016-03-28 |
| Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)NCT01979016results2020-03-18Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Dupilumab, Placebo · Other: Background treatment | Atopic Dermatitis (AD) | 54 | 2014-12-31actual | — | 2020-03-18 |
| Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMDNCT02061865SafetyOpen-label · Treatment | Phase 1 | Completed | Drug: REGN2176-3 | Neovascular Wet Age-related Macular Degeneration (AMD) | 12 | Dec 2014actual | — | 2015-02-11 |
| Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid MalignanciesNCT01688960Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: nesvacumab (REGN910/ SAR307746), nesvacumab (REGN910/ SAR307746), nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept), aflibercept (ziv-aflibercept) | Solid Tumors | 48 | Nov 2014actual | — | 2015-03-17 |
| Study of Nesvacumab (REGN910/ SAR307746)NCT01271972Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) in patients with advanced solid malignanciesNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: nesvacumab (REGN910/ SAR307746) | Solid Tumors | 53 | Sep 2014actual | — | 2015-06-16 |
| Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy VolunteersNCT01893528Number of TEAEsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: REGN2009 · Other: placebo | Healthy Volunteers | 49 | Sep 2014actual | — | 2014-11-10 |
| Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)NCT01926782results2017-03-21Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT AnalysisRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo (for alirocumab), Alirocumab, Statin | Hypercholesterolemia | 803 | Sep 2014actual | — | 2017-03-21 |
| Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)NCT01910220Percent change in total lean massRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: REGN1033 (SAR391786) · Other: placebo | Healthy Volunteers | 125 | Jun 2014actual | — | 2014-11-10 |
| A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneNCT01604824results2020-06-17Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Alirocumab, Placebo | Hypercholesterolemia | 23 | 2014-06-02actual | — | 2020-06-17 |
| Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)NCT01709500results2015-10-28Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) AnalysisRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: LMT (atorvastatin, simvastatin, or rosuvastatin), alirocumab, Placebo | Heterozygous Familial Hypercholesterolemia | 249 | May 2014actual | — | 2015-10-28 |
| Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)NCT01709513results2015-08-28Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) AnalysisRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin, Ezetimibe, Alirocumab, Placebo | Hypercholesterolemia | 314 | 2014-05-31actual | — | 2020-06-23 |
| Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisNCT01859988results2017-08-28Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Dupilumab, Placebo | Atopic Dermatitis | 380 | May 2014actual | — | 2017-08-28 |
| Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult SubjectsNCT01922661SafetyRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: REGN1908-1909 · Other: placebo | Allergy | 24 | May 2014actual | — | 2014-06-10 |
| Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)NCT01730040results2015-08-31Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) AnalysisRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo | Hypercholesterolemia | 355 | Apr 2014actual | — | 2015-08-31 |
| Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)NCT01730053results2015-10-28Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) AnalysisRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Alirocumab, Rosuvastatin, Ezetimibe, Placebo | Hypercholesterolemia | 305 | 2014-04-30actual | — | 2020-04-07 |
| A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid MalignanciesNCT00871559Safety and tolerabilityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: REGN421(SAR153192) | Advanced Solid Malignancies | 83 | Feb 2014actual | — | 2014-03-26 |
| Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)NCT00964795results2015-03-23Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMDOpen-label · Treatment | Phase 3 | Completed | Drug: Intravitreal Aflibercept Injection 2mg | Neovascular Age-related Macular Degeneration | 323 | Aug 2013actual | — | 2015-03-23 |
| Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)NCT01521559results2014-11-13Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCFRandomized · Double-masked · Treatment | Phase 3 | Completed | Procedure: Macular Laser Photocoagulation · Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Branch Retinal Vein Occlusion | 183 | Aug 2013actual | — | 2014-11-13 |
| Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout FlaresNCT01459796results2017-07-18Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 3 | Terminated | Drug: Rilonacept, Placebo, Allopurinol | Gout | 220 | Jun 2013actual | — | 2017-07-18 |
| Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)NCT01720576Number of TEAEsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN1033 (SAR391786), Placebo | Healthy Volunteers | 60 | Jun 2013actual | — | 2013-09-12 |
| Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic DermatitisNCT01605708Clinical ActivityRandomized · Triple-masked · Treatment | Phase 1/2 | Terminated | Drug: REGN846 | Pruritus, Atopic Dermatitis | 19 | Apr 2013actual | — | 2013-10-28 |
| Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic DermatitisNCT01548404results2018-08-10Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Dupilumab | Atopic Dermatitis | 109 | Mar 2013actual | — | 2018-08-10 |
| Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular EdemaNCT01363440results2015-04-20Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) · Procedure: Macular Laser Photocoagulation | Diabetic Macular Edema | 466 | Jan 2013actual | — | 2016-05-30 |
| Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy VolunteersNCT01540539Total number and severity of TEAEsRandomized · Triple-masked | Phase 1 | Completed | Drug: REGN1154 or placebo | Healthy Volunteers | 44 | Jan 2013actual | — | 2014-01-24 |
| Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)NCT01639040results2017-10-13Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Dupilumab, Placebo (for Dupilumab) · Other: Topical Corticosteroid (TCS) | Atopic Dermatitis | 31 | Dec 2012actual | — | 2017-10-13 |
| A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)NCT01507402Number of TEAEsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: REGN1033(SAR391786), REGN1033(SAR391786), Placebo | Healthy Volunteers | 76 | Nov 2012actual | — | 2012-11-14 |
| Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of AllopurinolNCT01451645results2014-05-12Number of Gout Flares Per Participant From Day 1 to Week 16Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Colchicine (Colcrys®), placebo, allopurinol | Intercritical Gout | 82 | Aug 2012actual | — | 2014-05-12 |
| Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic DermatitisNCT01259323The primary endpoint in the study is the incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN668 or Placebo from baseline through week 12.Randomized · Double-masked · Treatment | Phase 1 | Completed | Biological: REGN668, REGN668, REGN668 | Dermatitis | 30 | Jul 2012actual | — | 2012-10-04 |
| Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy VolunteersNCT01197391The primary endpoint in the study is the percentage of subjects with treatment emergent adverse events, reported from the administration of study drug on day 1 to the completion of the study on day 106.Randomized · Double-masked · Treatment | Phase 1 | Completed | Biological: REGN728 | Healthy | 48 | Mar 2012actual | — | 2012-11-12 |
| Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic DermatitisNCT01385657Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, Dupilumab · Other: Background treatment | Atopic Dermatitis | 37 | 2012-03-31actual | — | 2020-02-26 |
| Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy VolunteersNCT01484600Incidence and severity of treatment-emergent adverse events (TEAEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: REGN668: Injection Rate 1, REGN668: Injection Rate 2 | Healthy | 36 | Feb 2012actual | — | 2012-03-14 |
| Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH HypercholesterolemiaNCT01266876results2015-09-22Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment AnalysisRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Alirocumab, Placebo | Hypercholesterolemia | 77 | Nov 2011actual | — | 2015-09-22 |
| Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMDNCT00527423results2013-06-12Number of Participants With Adverse Events (AE)Single-masked · Treatment | Phase 2 | Completed | Drug: VEGF Trap Eye | Macular Degeneration | 157 | Oct 2011actual | — | 2013-06-12 |
| Safety and Tolerability Study of REGN846 (SAR302352) in Healthy VolunteersNCT01209793Incidence and severity of adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: REGN846 | Healthy | 40 | Sep 2011actual | — | 2012-06-01 |
| A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced CarcinomaNCT00794417results2020-12-10Phase 1: Recommended Dose of Aflibercept for Phase 2Non-randomized · Open-label · Treatment | Phase 1/2 | Terminated | Drug: Aflibercept, Pemetrexed, Cisplatin | Advanced Carcinoma, Non-small Cell Lung Cancer | 60 | 2011-06-30actual | — | 2020-12-10 |
| Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinNCT01161082The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: REGN727(SAR236553) | Hypercholesterolemia | 72 | May 2011actual | — | 2015-01-27 |
| Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)NCT00856206results2017-04-28Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: Rilonacept · Other: Placebo | Gout | 1,315 | Jan 2011actual | — | 2017-04-28 |
| Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture PainNCT01001715Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale [PI-NRS]Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business decision due to low subject recruitment and enrollment | Drug: REGN475/SAR164877, Placebo (for REGN475/SAR164877) | Back Pain | 41 | Jan 2011actual | — | 2013-05-27 |
| Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis PainNCT01001923Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business decision due to low subject recruitment and enrollment | Drug: REGN475/SAR164877, Placebo (for REGN475/SAR164877) | Abdominal Pain Upper | 15 | Jan 2011actual | — | 2013-05-27 |
| PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)NCT00958438results2017-04-28Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Rilonacept, Rilonacept | Gout | 248 | Dec 2010actual | — | 2017-04-28 |
| A Study of Tocilizumab in Patients With Rheumatoid ArthritisNCT01187563observationalSafety (clinical and laboratory parameters) | — | Completed | — | Rheumatoid Arthritis | 16 | Dec 2010actual | — | 2011-10-13 |
| Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy VolunteersNCT01074372The incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: REGN727, Placebo | Healthy Volunteers | 32 | Nov 2010actual | — | 2015-01-27 |
| Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)NCT00943072results2013-05-27Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: VEGF Trap-Eye 2.0mg · Drug: Sham | Macular Edema Secondary to Central Retinal Vein Occlusion | 189 | Oct 2010actual | — | 2013-05-27 |
| Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy VolunteersNCT01026597The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: REGN727, Placebo | Healthy | 40 | Oct 2010actual | — | 2015-01-27 |
| Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)NCT00509795results2012-04-16Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Macular Degeneration | 1,217 | Sep 2010actual | — | 2012-12-28 |
| Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy VolunteersNCT01015027The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN668 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 85/visit 11.Randomized · Double-masked · Treatment | Phase 1 | Completed | Biological: REGN668 | Healthy | 48 | Jul 2010actual | — | 2013-06-17 |
| PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1NCT00829829results2017-04-28Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Other: Placebo · Drug: Rilonacept 80 mg, Rilonacept 160 mg | Intercritical Gout | 241 | May 2010actual | — | 2017-04-28 |
| A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the KneeNCT00944892The incidence of TEAEs in patients treated with REGN475 or placebo, reported between administration of study drug on Day 1 and the completion of study at the end of week 24 (Day 169).Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: REGN475 · Other: Placebo | Osteoarthritis of the Knee | 200 | May 2010actual | — | 2011-12-08 |
| A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic PainNCT00991172Sciatic pain between baseline and end of week 4Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: REGN475, REGN475, Placebo Injection | Sciatica | 159 | May 2010actual | — | 2011-12-08 |
| Study Utilizing Rilonacept in Gout ExacerbationsNCT00855920results2017-04-28Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 HoursRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Rilonacept, Indomethacin · Other: Placebo (for Indomethacin), Placebo (for Rilonacept) | Acute Gout Flare | 225 | Feb 2010actual | — | 2017-04-28 |
| DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical ImpactNCT00789477results2014-09-09Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Procedure: Laser Photocoagulation · Drug: Intravitreal Aflibercept Injection | Diabetic Macular Edema | 221 | Dec 2009actual | — | 2014-09-09 |
| A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy SubjectsNCT00856310Incidence of treatment emergent adverse events in subjects treated with REGN475 or placebo.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Biological: REGN475 (SAR164877) | Healthy | 56 | Nov 2009actual | — | 2012-05-10 |
| A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis SubjectsNCT01011959Incidence of treatment-emergent adverse events in patients treated with REGN88 and placeboRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: REGN88 | Rheumatoid Arthritis | 60 | Aug 2009actual | — | 2013-09-30 |
| A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid ArthritisNCT01026519hs-C reactive protein (hs-CRP)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: REGN88 · Other: Placebo | Rheumatoid Arthritis | 32 | Mar 2009actual | — | 2013-09-30 |
| Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid ArthritisNCT01055899To assess the safety and tolerability of a single dose of subcutaneously administered REGN88 in subjects with rheumatoid arthritis who are receiving concomitant treatment with methotrexateRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: REGN88, REGN88, REGN88 | Rheumatoid Arthritis | 15 | Mar 2009actual | — | 2013-09-30 |
| Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout FlaresNCT00610363results2017-05-02Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Rilonacept · Other: Placebo (for Rilonacept) | Gout | 83 | Oct 2008actual | — | 2017-05-02 |
| Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)NCT00288704results2009-11-13Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: rilonacept 160 mg, Placebo, rilonacept 160 mg | Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn | 104 | Jun 2008actual | — | 2011-12-06 |
| Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMDNCT00320775Safety and tolerability, bioeffectRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: VEGF Trap | Macular Degeneration | 51 | Jun 2008actual | — | 2015-03-18 |
| Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)NCT00320788results2012-03-01Mean Change of CR/LT From Baseline at Week 12Randomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321), aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Macular Degeneration | 159 | Jun 2008actual | — | 2012-03-01 |
| Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)NCT01803321Frequency of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: rilonacept (IL-1 Trap) · Other: Placebo | Systemic Juvenile Idiopathic Arthritis | 24 | Jun 2008actual | — | 2013-03-04 |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00082823Open-label · Treatment | Phase 1 | Completed | Biological: ziv-aflibercept | Cancer | 25 | May 2008actual | — | 2016-06-03 |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00083213Open-label · Treatment | Phase 1 | Completed | Biological: ziv-aflibercept | Cancer | 25 | May 2008actual | — | 2016-06-03 |
| Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMDNCT00383370The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: VEGF Trap · Biological: VEGF Trap | Neovascular Age Related Macular Degeneration | 20 | Sep 2007actual | — | 2011-04-21 |
| VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's LymphomaNCT00045266Open-label · Treatment | Phase 1 | Completed | Biological: ziv-aflibercept | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | — | Feb 2007actual | — | 2016-06-03 |
| Phase 1 Study of VEGF Trap in Patients With Diabetic Macular EdemaNCT00320814To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: VEGF Trap-Eye | Diabetic Macular Edema | 5 | Aug 2006actual | — | 2011-06-10 |
| VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's LymphomaNCT00036946Treatment | Phase 1 | Completed | Biological: ziv-aflibercept | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | — | Mar 2002actual | — | 2016-06-03 |
| Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and AnemiaNCT00609544Change in blood hemoglobin concentration.Randomized · Triple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Unable to enroll patients | Drug: Rilonacept | Chronic Kidney Disease, Anemia | 0 | — | — | 2011-04-19 |
| Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal InjuryNCT01053702Change in procedural pain intensityRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: R475, Placebo | Thermal Injury Pain | 0 | — | — | 2011-04-19 |
| A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the KneeNCT01239017The incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN475 or placebo.Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawn | Biological: REGN475 · Other: Placebo | Osteoarthritis | 0 | — | — | 2015-03-18 |
| Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaNCT03492489expanded access | — | No longer available | Drug: cemiplimab | Cutaneous Squamous Cell Carcinoma | — | — | — | 2019-08-01 |
| R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus DiseaseNCT03576690expanded access | — | Available | Biological: REGN3470-3471-3479 | Ebola Virus Disease | — | — | — | 2025-11-24 |
| Compassionate Use of REGN-COV2 for the Treatment of COVID-19NCT04617535expanded access | — | No longer available | Drug: REGN10933+REGN10987 combination therapy | COVID-19 | — | — | — | 2023-10-03 |
| Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin SignalingNCT04710056expanded access | — | Available | Drug: REGN4461 | Lipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB) | — | — | — | 2026-03-12 |
| Compassionate Use of DupilumabNCT04776694expanded access | — | Approved for marketing | Drug: Dupilumab | Type 2 Inflammatory Disorders | — | — | — | 2025-09-22 |
| Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)NCT05164250expanded access | — | Approved for marketing | Drug: REGN5458 | Multiple Myeloma | — | — | — | 2025-11-10 |
| Compassionate Use of PozelimabNCT05232110expanded access | — | Approved for marketing | Drug: Pozelimab | CD55-deficient Protein-losing Enteropathy | — | — | — | 2025-11-10 |
| A Compassionate Use (CU) Program of OdronextamabNCT05619367expanded access | — | Available | Drug: Odronextamab | Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL), High-Grade B-Cell Lymphoma (HGBCL) | — | — | — | 2025-12-23 |
| Compassionate Use of Dupilumab for Adult Patients With Bullous PemphigoidNCT05906706expanded access | — | Approved for marketing | Drug: dupilumab | Bullous Pemphigoid | — | — | — | 2025-07-03 |
| Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing EnteropathyNCT06003881expanded access | — | Approved for marketing | Drug: Pozelimab | CD55-Deficient Protein-Losing Enteropathy | — | — | — | 2025-11-10 |
| Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT06028594expanded access | — | No longer available | Drug: Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | — | — | — | 2025-10-20 |
| Compassionate Use of VidutolimodNCT06063746expanded access | — | No longer available | Drug: Vidutolimod | Refractory Melanoma | — | — | — | 2026-01-08 |
| Expanded Access Use of Cemiplimab in Patients With Solid TumorsNCT06132191expanded access | — | Approved for marketing | Drug: Cemiplimab | Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC) | — | — | — | 2025-11-20 |
| Compassionate Use of EvinacumabNCT06500598expanded access | — | Approved for marketing | Drug: Evinacumab | Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG), Dysbetalipoproteinemia (DBL) | — | — | — | 2025-10-28 |
| Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With LinvoseltamabNCT06631677expanded access | — | Available | Drug: Dupilumab | Food Allergy | — | — | — | 2026-06-26 |
| An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)NCT07301450expanded access | — | Temporarily not available | Drug: Garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | — | — | — | 2025-12-24 |
| Compassionate Use of UbamatamabNCT07502716expanded access | — | Available | Drug: ubamatamab | Renal Medullary Carcinoma (RMC), Epithelioid Sarcoma | — | — | — | 2026-03-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19